Texas Oncology - West Texas

Running trials

• Recruiting

  Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

  NCT07578649· Phase 3· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Source

• Active, not recruiting

  BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

  NCT06773910· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Phase 1/2· Source

• Active, not recruiting

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Endometrial cancer2 recruiting
• Lung cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Gastric and esophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Phase 2· Source